Defining CD95 as a tumor suppressor gene

Journal of Molecular Medicine

Volumn 78, Issue 6, 2000, Pages 312-325

  Muschen M ^a   Warskulat, U ^b   Beckmann, M W ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Antitumor immunity; Apoptosis; Differentiation; Invasion; Somatic mutations; Tolerance

Indexed keywords

FAS ANTIGEN; LIGAND;

APOPTOSIS; CANCER; CANCER INVASION; DIFFERENTIATION; GENE FUNCTION; GENE LOSS; GRAFT REJECTION; HUMAN; IMMUNOLOGICAL TOLERANCE; METASTASIS; NONHUMAN; REVIEW; SOMATIC MUTATION; TUMOR ESCAPE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR SUPPRESSOR GENE;

EID: 0033850799     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001090000112     Document Type: Review

References (121)

1. Monoclonal antibody-mediated tumor regression by induction of apoptosis
2. A cell killing monoclonal antibody (anti-Fas) to a cell surface antigen co-down-regulated with the receptor of tumor necrosis factor
3. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis
4. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family
5. Constitutive and induced expression of Apo-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells
6. A role for CD95 ligand in preventing graft rejection
7. Fas ligand-induced apoptosis as a mechanism of immune privilege
8. Involvement of CD95 (Apo-1/Fas) ligand expressed by rat Kupffer cells in hepatic immunoregulation
9. Regulation of CD95 receptor and ligand expression by lipopolysaccharide and dexamethasone in parenchymal and non-parenchymal rat liver cells
10. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule
11. A naturally occurring soluble isoform of murine Fas generated by alternative splicing
12. Deranged CD95 system in a case of Churg-Strauss vasculitis
13. Involvement of soluble CD95 in Churg-Strauss syndrome
14. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis
15. The role of Fas in autoimmune diabetes
16. Fas Ligand in human serum
17. Metalloproteinase-mediated release of human Fas ligand
18. Regulation of CD95 (Apo-1/Fas) Ligand and receptor expression in human embryonal carcinoma cells by interferon γ and all-trans retinoic acid
19. Regulation of CD95 (Apo-1/Fas) Ligand and receptor expression in squamous cell carcinoma by cisplatin and interferon γ
20. CD95 Ligand expression in dedifferentiated breast cancer
21. CD95 Ligand expression as a mechanism of immune escape in breast cancer
22. Downregulation of Fas ligand by shedding
23. Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity
24. Fas expression and function in normal and malignant breast cell lines
25. Downregulation of Fas gene expression in colon cancer is not a result of allelic loss or gene rearrangement
26. + large granular lymphocyte leukemia
27. p53 activates the CD95 (Apo-1/Fas) gene in response to DNA damage by anticancer drugs
28. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis
29. Differential involvement of the CD95 (Apo-1/Fas) receptor/ligand system on apoptosis induced by the wild-type p53 gene transfer in human cancer cells
30. Bax is frequently compromised in Burkitt's lymphoma with irreversible resistance to Fasinduced apoptosis
31. The Fas/Fas-ligand system: A mechanism for immune evasion in human breast cancer
32. Expression of Fas (CD95/Apo-1) and Fas ligand in lung cancer, its prognostic and predictive relevance
33. Suppression of Fas receptor and negative correlation of Fas ligand with differentiation and apoptosis in oral squamous cell carcinoma
34. Expression of Fas and Fas ligand in Hodgkin's disease
35. Fas and Fas ligand expression in tumor cells and in vascular smooth-muscle cells of colonic and renal carcinomas
36. Prognostic significance of Fas and Fas ligand expression in human esophageal cancer
37. Fas/Fas ligand interaction in human colorectal hepatic metastases: A mechanism of hepatocyte destruction to facilitate local tumor invasion
38. Lymphocyte apoptosis by CD95 (Apo-1/Fas) ligand-expressing tumor cells - A mechanism of immune evasion
39. Melanoma cell expression of Fas (Apo-1/CD95) Ligand: Implications for tumor immune escape
40. Involvement of the CD95 (Apo-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells
41. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand
42. Fas ligand expression by astrocytoma in vivo: Maintaining immune privilege in the brain?
43. Human lung carcinomas express Fas ligand
44. Fas ligand is not only expressed in immune privileged human organs but is also coexpressed with Fas in various epithelial tissues
45. Immunohistochemical analysis of Fas ligand expression in sarcomas. Sarcomas express high levels of Fas ligand in vivo
46. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes
47. Fas ligand expression in primary colon adenocarcinomas: Evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer
48. Expression of Fas ligand by human gastric adenocarcinomas: A potential mechanism of immune escape in stomach cancer
49. Fas (CD95) ligand expression by tumor cells can be unrelated to their capacity to induce tolerance or immune rejection
50. Relationship between Fas-ligand expression on carcinoma cell and cytotoxic T-lymphocyte response in lymphoepithelioma-like cancer of the stomach
51. Transitional cell carcinoma expresses high levels of Fas ligand in vivo
52. Fas ligand is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas
53. Fas ligand expression in thyroid carcinomas: A potential mechanism of immune evasion
54. Expression of Fas (CD95/Apo-1) ligand by human breast cancers: Significance for tumor immune privilege
55. Apoptosis and tumorigenesis in human cholangiocarcinoma cells. Involvement of Fas/Apo-1 (CD95) and calmodulin
56. Predominant expression of Fas (CD95/Apo-1) ligand in metastatic melanoma revealed by longitudinal analysis
57. Immunological escape mechanism in pancreatic carcinoma
58. Immunoregulation in pancreatic cancer patients
59. The Fas counterattack in vivo: Apoptotic depletion of tumor-infiltrating lymphocytes associated with fas ligand expression by human esophageal carcinoma
60. CD95 ligand expression as a criterion of malignant transformation in breast cancer
61. Analysis of Fas and Fas ligand expression and function in lung cancer cell lines
62. FasL:Fas ratio - A prognostic factor in breast carcinomas
63. Human astrocytomas co-expressing Fas and Fas ligand also produce TGBβ2 and Bcl-2
64. Fas ligand is expressed in normal breast epithelial cells and is frequently upregulated in breast cancer
65. Targeted mutation of the Fas gene causes hyperplasia in peripheral lymphoid organs and liver
66. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis
67. Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas Ligand interactions
68. Fas gene mutations in the Canale Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity
69. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity
70. Clinical, immunological and pathological consequences of Fas-deficient conditions
71. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome
72. Identification of new Fas mutations in a patient with autoimmune lymphoproliferative syndrome (ALPS) and eosinophilia
73. The molecular basis for apoptotic defects in patients with CD95 (Apo-1/Fas) mutations
74. Chronic lymphadenopathy simulating malignant lymphoma
75. Pathological findings in human autoimmune lymphoproliferative syndrome
76. Defective apoptosis due to a point mutation in the death domain of CD95 associated with autoimmune lymphoproliferative syndrome, T-cell lymphoma, and Hodgkin's disease
77. Search for rearrangements and/or allelic loss of the Fas/Apo-1 gene in 101 human lymphomas
78. Mutations in the Fas antigen in patients with multiple myeloma
79. Apoptosis in a Fas-resistant, T cell receptor-sensitive human leukaemic T-cell clone
80. Somatic Fas mutations in non-Hodgkin's lymphoma: Association with extranodal disease and autoimmunity
81. CD95 (Apo-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia
82. Mutation of CD95 (Apo-1/Fas) gene in adult T-cell leukemia cells
83. Fas gene mutation in the progression of adult T cell leukemia
84. BCL-6 mutations in normal germinal center B cells: Evidence of somatic hypermutation acting outside Ig loci
85. Rare occurrence of classical Hodgkin's disease as a T cell lymphoma
86. The origin of Hodgkin- and Reed-Sternberg cells in Hodgkin's disease
87. Clonal selection and learning in the antibody system
88. Mutation analysis of CD95 (Apo-1/Fas) in childhood B-lineage acute lymphoblastic leukaemia
89. Alterations of Fas (Apo-1/CD95) gene in transitional cell carcinomas of urinary bladder
90. Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer
91. Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma
92. Somatic mutations of Fas (Apo-1/CD95) gene in cutaneous squamous cell carcinoma arising from a burn scan
93. Mutation and cancer: Statistical study of retinoblastoma
94. Death pathway genes Fas (Apo-1/CD95) and Bik (Nbk) show no mutations in colorectal carcinomas
95. A novel protein domain required for apoptosis. Mutational analysis of the human Fas antigen
96. Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis
97. Oncogenic Ras inhibits Fas ligand-mediated apoptosis by downregulating the expression of Fas
98. Cell surface trafficking of Fas: A rapid mechanism of p53-mediated apoptosis
99. Transcriptional regulation of Fas gene expression by GA-binding protein and AP-1 in T cell antigen receptor-CD3-complex-stimulated T cells
100. PML is essential for multiple apoptotic pathways
101. Regulation of the Fas apoptotic cell death pathway by Abl
102. A genetic model for colorectal tumorigenesis
103. Fas and FasL in the homeostatic regulation of immune responses
104. Expression of Fas (Apo-1/CD95) in tumor infiltrating and peripheral blood lymphocytes in patients with renal cell carcinoma
105. Inhibition of the alloantibody response by CD95 ligand
106. An aggressive nasal lymphoma accompanied by high levels of soluble Fas ligand
107. Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus
108. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival
109. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction
110. Fas Ligand, TNFα expression and apoptosis during acute allograft rejection and tolerance
111. Gene transfer of Fas ligand induces tumor regression in vivo
112. Regulation of the proinflammatory effects of Fas ligand (CD95L)
113. A critical role for Transforming Growth Factor β (TGF-β) in donor transfusion-induced allograft tolerance
114. Recombinant IFN-gamma abrogates allograft tolerance induced by donor-specific blood transfusion by restoring alloantibody-production
115. Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase
116. Differential increase of Fas ligand expression on metastatic and thin or thick primary melanoma cells compared with interleukin-10
117. Fas and Fas ligand interactions suppress melanoma lung metastasis
118. Multistep carcinogenesis of breast cancer and tumor heterogeneity
119. Lack of CD95/Fas gene somatic mutations in extranodal, nodal and splenic marginal zone B cell lymphomas
120. Cultivated H/RS cells are resistant to CD95L-mediated apoptosis despite expression of wild-type CD95
121. Fas ligand: A sensor for DNA damage critical in skin cancer etiology